scholarly journals Tumor sincrónico de endometrio y ovario. Patología infrecuente en ginecología oncológica

2020 ◽  
Vol 80 (04) ◽  
pp. 348-355
Author(s):  
Alba Rodríguez ◽  
◽  
Jara Gallardo ◽  
Zoraida Frías ◽  
Manuel Pantoja ◽  
...  
Keyword(s):  
Metastatic Tumor ◽  
Figo Stage ◽  
Tumor Stage ◽  
The United States ◽  
Ovarian Neoplasm ◽  
Synchronous Tumor ◽  
Endometrial Tumor ◽  
Synchronous Neoplasm ◽  
Gynecological Tumor ◽  
Multiple Primary Neoplasm

Endometrial cancer remains the most common gynecological tumor in women in the United States of America. The simultaneous finding of endometrial and ovarian neoplasm, as a synchronous tumor, accounts for about 5 - 10 % of endometrial and ovarian tumors. Therefore, is a rare entity. Consideration as restricted metastases or pseudometastasis to define the spread of this kind of tumor, is becoming more relevant nowadays thanks to the latest advances in the field of immunohistochemistry and molecular biology. In this article we present the case of a 57-year-old patient initially diagnosed with FIGO stage IIIA endometrial carcinoma; subsequently, it was a synchronous endometrial tumor stage IB and IC ovary, despite the presurgical suspicion of a metastatic tumor. Keywords: Endometrial Neoplasm, Ovarian Neoplasm, Synchronous Neoplasm, Multiple Primary Neoplasm, Neoplasm Metastasis.

scholarly journals Presentation, Management, and Outcomes across the Rural-Urban Continuum for Hepatocellular Carcinoma

2020 ◽  
Author(s):  
Kali Zhou ◽  
Trevor A Pickering ◽  
Christina S Gainey ◽  
Myles Cockburn ◽  
Mariana C Stern ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Rural Communities ◽  
Urban Areas ◽  
Tumor Stage ◽  
The United States ◽  
Population Based ◽  
Urban Residents ◽  
Place Of Residence ◽  
Incidence And Mortality ◽  
Receive Treatment

Abstract Background Hepatocellular carcinoma is one of few cancers with rising incidence and mortality in the United States. Little is known about disease presentation and outcomes across the rural-urban continuum. Methods Using the population-based SEER registry, we identified adults with incident hepatocellular carcinoma between 2000–2016. Urban, suburban and rural residence at time of cancer diagnosis were categorized by the Census Bureau’s percent of the population living in non-urban areas. We examined association between place of residence and overall survival. Secondary outcomes were late tumor stage and receipt of therapy. Results Of 83,368 cases, 75.8%, 20.4%, and 3.8% lived in urban, suburban, and rural communities, respectively. Median survival was 7 months (IQR 2–24). All stage and stage-specific survival differed by place of residence, except for distant stage. In adjusted models, rural and suburban residents had a respective 1.09-fold (95% CI = 1.04–1.14, p < .001) and 1.08-fold (95% CI = 1.05–1.10, p < .001) increased hazard of overall mortality as compared to urban residents. Furthermore, rural and suburban residents had 18% (OR = 1.18, 95% CI 1.10–1.27, p < .001) and 5% (OR = 1.05, 95% CI = 1.02–1.09, p = .003) higher odds of diagnosis at late stage and were 12% (OR = 0.88, 95% CI = 0.80–0.94, p < .001) and 8% (OR = 0.92, 95% CI = 0.88–0.95, p < .001) less likely to receive treatment, respectively, compared to urban residents. Conclusions Residence in a suburban and rural community at time of diagnosis was independently associated with worse indicators across the cancer continuum for liver cancer. Further research is needed to elucidate the primary drivers of these rural-urban disparities.

Endometrial lymphoepitheliomalike carcinoma: absence of Epstein–Barr virus genomes

2007 ◽  
Vol 17 (2) ◽  
pp. 532-535 ◽  
Author(s):  
S. Rahimi ◽  
A. Lena ◽  
G. Vittori
Keyword(s):  
Endometrial Carcinoma ◽  
Epstein Barr Virus ◽  
Neuron Specific Enolase ◽  
Progesterone Receptors ◽  
Figo Stage ◽  
Barr Virus ◽  
Ebv Infection ◽  
Endometrial Tumor ◽  
Epstein Barr ◽  
Virus Genomes

The aim of this study was to report a case of primary lymphoepitheliomalike endometrial carcinoma (FIGO stage IB). A 57-year-old woman presented with an endometrial tumor showing the classic clinical and hysteroscopic aspects of endometrial carcinoma. Morphologically, the neoplasm was similar to undifferentiated nasopharyngeal carcinoma (lymphoepithelioma). Immunohistochemistry showed that the tumor cells were cyokeratins and epithelial membrane antigen positive. Leucocyte common antigen, estrogen and progesterone receptors, neuron specific enolase, cromogranin, synaptophysin, and p53 were negative. We did not find evidence of Epstein–Barr virus (EBV) infection using immunohistochemistry and polymerase chain reaction (PCR). We report the third case of an endometrial lymphoepitheliomalike carcinoma (LELC). The patient did not receive chemotherapy and is alive and free of disease 24 month after diagnosis. LELC can occur in the endometrium and in this location may not be associated with EBV infection

Colorectal Carcinoma: Selected Issues in Pathologic Examination and Staging and Determination of Prognostic Factors

2008 ◽  
Vol 132 (10) ◽  
pp. 1600-1607 ◽  
Author(s):  
Mary Kay Washington
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Colorectal Carcinoma ◽  
Clinical Care ◽  
Treatment Strategies ◽  
Staging System ◽  
Tumor Stage ◽  
The United States ◽  
Lymphatic Invasion ◽  
Pathologic Staging

Abstract Context.—Colorectal carcinoma is one of the most common types of cancer in Western countries and is consistently ranked among the top 3 causes of cancer-related deaths, with approximately 150 000 new cases in the United States and 55 000 deaths in 2006. The pathologist's assessment of tumor stage and stage-independent morphologic features, such as vascular/lymphatic invasion, influences treatment strategies for the individual patient, such as the decision to offer adjuvant therapy after surgery. However, although the pathologist influences clinical care in colorectal cancer, certain aspects of staging and evaluation of prognostic factors remain challenging and confusing. Objectives.—To present the currently used colorectal cancer staging system; to address challenging areas in pathologic staging, including T category considerations and recommendations for the minimum number of lymph nodes sampled; and to discuss assessment of selected stage-independent prognostic factors, such as vascular/ lymphatic invasion. Data Sources.—This review is based on the current staging manual from the American Joint Committee on Cancer, the College of American Pathologists Protocol for Examination of Specimens From Patients With Primary Carcinomas of the Colon and Rectum, and selected articles pertaining to colorectal carcinoma staging and prognostic factors accessible through Ovid Medline (National Library of Medicine, Bethesda, Md). Conclusions.—Proper assessment of pathologic staging for colorectal cancer and of morphologic prognostic factors requires a thorough understanding of staging guidelines and careful specimen dissection and sampling.

Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: Effect on progression-free survival

2003 ◽  
Vol 13 (5) ◽  
pp. 633-639 ◽  
Author(s):  
A. Obermair ◽  
R. Cheuk ◽  
K. Horwood ◽  
M. Neudorfer ◽  
M. Janda ◽  
...  
Keyword(s):  
Cervical Carcinoma ◽  
Concurrent Chemoradiotherapy ◽  
Progression Free Survival ◽  
Figo Stage ◽  
Tumor Stage ◽  
Free Survival ◽  
Parametrial Involvement ◽  
The Impact ◽  
Relevant Factors

To determine the impact of anemia before and during chemoradiation in patients with cervical cancer, we collected data on hemoglobin (Hb) levels before and during treatment from 60 unselected patients with cervical carcinoma. All patients had FIGO stage IB to IVA disease and were treated with concurrent chemoradiation for the aim of cure. Patients with an Hb value below or equal to the lower 25th quartile were considered anemic. Progression-free survival (PFS) was evaluated by univariate and multivariate analyses. After a median follow-up of 26.3 months, 20 patients developed disease progression. The lowest Hb during chemoradiation (nadir Hb), the stage of disease, and parametrial involvement were correlated significantly with PFS. On multivariate analysis, the nadir Hb (relative risk [RR] 0.29) and tumor stage (RR 3.4) remained the only prognostically relevant factors predicting PFS. At 60 months the PFS was 39.1% for anemic patients and 48.0% for nonanemic patients (P < 0.0002). In patients undergoing chemoradiation for cervical carcinoma, a low nadir Hb is highly predictive of shortened PFS, whereas the Hb before treatment is prognostically not significant.

Patterns of care for FIGO stage IB-IIA cervical cancer across the United States

2017 ◽  
Vol 145 ◽  
pp. 181
Author(s):  
E. Pereira ◽  
N. Nair ◽  
M.A. Schwartz ◽  
J. Gorski ◽  
P. Dottino ◽  
...  
Keyword(s):  
United States ◽  
Cervical Cancer ◽  
Figo Stage ◽  
The United States ◽  
Patterns Of Care ◽  
Stage Ib

What are the expectations and preferences of patients with ovarian cancer to a maintenance therapy? A NOGGO/GCIG/ENGOT-ov22 survey (Expression IV) in 2101 patients.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e17096-e17096 ◽  
Author(s):  
Irena Rohr ◽  
Maren Keller ◽  
Radoslav Chekerov ◽  
Gülten Oskay-Özcelik ◽  
Rolf Richter ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Side Effects ◽  
Maintenance Therapy ◽  
Cancer Patients ◽  
Recurrent Disease ◽  
Figo Stage ◽  
Tumor Stage ◽  
Primary Diagnosis ◽  
Paper Version

e17096 Background: The primary aim of the survey was to investigate the expectations of European patients about maintenance therapy. Methods: A 24-item questionnaire was provided to ovarian cancer patients via internet or paper-version in9 European countries (Austria, Belgium, France, Germany, Italy, Romania, Slovenia, Finland and Turkey). Data was captured about demographics, tumor stage and therapy after first line and/ or recurrent disease and particularly about preferences of administration and expectations concerning a maintenance therapy. Results: Overall, 2101 questionnaires of ovarian cancer patients were evaluated. Over 63% of the patients were between 51 and 70 years (range 18-90). The majority of the patients were FIGO stage III at their primary diagnosis. 96% of the patients had a surgery and 93% received a chemotherapy. 38% of respondents had recurrent disease. 45% of the patients had already heard of and 29% received maintenance therapy. 85% of the patients heard about maintenance therapy from the doctor and 10% from other patients and 9% read about it on the internet. The four most disturbing side effects of maintenance therapy were polyneuropathy (37%), nausea (36%), loss of hair (34%) and vomiting (34%). The main objective of maintenance treatment for all patients was to increase the chances of cure (73%), followed by an improvement in the quality of life (47%) and the delay of tumor growth (37%). Many patients are willing to take a maintenance therapy until tumor progression (38%). 39% of the patients would prefer an oral administration and 29% do not have any preference for any specific administration. When we performed cross country sub-analysis between patients with primary diagnosis and relapse, or sub-analysis between patients who are actually receiving maintenance therapy or not, we observed no significant differences of expectations to a maintenance therapy. Conclusions: There is an urgent need for more information regarding side effects and treatment goals of maintenance therapy to avoid misunderstandings by the patient. This information may increase patient’s compliance for maintenance therapy in ovarian cancer.

Use of clinical classification software to differentiate good versus poor prognostic patients with ovarian cancer: A SEER-Medicare database analysis from the viera study.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e18069-e18069
Author(s):  
Gboyega Adeboyeje ◽  
Kaushal Desai ◽  
Shahed Iqbal ◽  
Jinghua He ◽  
Matthew J. Monberg
Keyword(s):  
Ovarian Cancer ◽  
Liver Disease ◽  
Stage Iv ◽  
Figo Stage ◽  
The United States ◽  
Baseline Period ◽  
Good Prognosis ◽  
Clinical Classification ◽  
Clinical Classification Software ◽  
Medicare Database

e18069 Background: Historically, recurrence in ovarian cancer (OC) following first-line (1L) chemotherapy (CT) occurs in up to 80% of patients within 2 years. The Clinical Classification Software (CCS) systematically classifies thousands of ICD-9 codes into a smaller number of clinically meaningful categories. We sought to use CCS and other routinely collected variables to differentiate the clinical and demographic profiles of patients with good prognosis (GP) versus poor prognosis (PP) in the United States (US). Methods: This was a retrospective cohort study of newly diagnosed (FIGO stage II - IV), treatment-naïve patients, ≥ 66 years, who received 4-10 cycles of platinum-based 1L CT between Jan 2009 - Dec 2015 using the SEER-Medicare database, a nationally representative cancer registry. Patient were assumed to have progressed to a subsequent line of therapy following a gap between consecutive CT cycles ≥ 63 days. Patients were classified as GP if alive ≥4 years with no further treatment following 1L CT; PP was defined as receipt of ≥2L CT within 12 months of initial 1L CT. Demographic and prognostic characteristics were assessed during a 6-month baseline period prior to initiation of 1L CT. We assessed clinically meaningful differences in baseline characteristics with absolute standardized differences (ASD) using a threshold of 0.1 (indicating negligible difference between two cohorts). Results: There were a total of 2,262 patients (mean age: 74.6 ±6.2 years) including 251 GP (11%) and 209 PP (9%) patients (table below). PP patients were significantly more likely to be older than 70 years, and present at stage IV, liver disease and ascites, and anemia at diagnosis. PP patients were also less likely to have primary debulking surgery. Conclusions: Approximately one tenth of OC patients received no further treatment 4 years after the initial treatment with contemporary standard of care. GP may be differentiated from PP on the basis of commonly used clinical characteristics such as stage and also specific comorbidities such as liver disease and ascites. [Table: see text]

scholarly journals Incidence and characteristics of death from peptic ulcer among cancer patients in the United States

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Pengcheng Yang ◽  
Yongqiang Zheng ◽  
Lei Zhang ◽  
Xiaohua Hou
Keyword(s):  
Peptic Ulcer ◽  
Mortality Rate ◽  
Cancer Patients ◽  
Digestive System ◽  
Tumor Stage ◽  
The United States ◽  
Standardized Mortality Ratio ◽  
Peptic Ulcers ◽  
Lung Cancer Patients ◽  
Mortality Ratio

AbstractMost cancer patients die of non-cancer causes, and peptic ulcer is one cause that deserves attention. To characterize the incidence and risk factors of death from peptic ulcer among cancer patients, we extracted the data of cancer patients registered in the Surveillance Epidemiology and End Results (SEER) program from 1975 to 2016. Out of the 8,471,051 patients extracted from SEER, 4,698 died from peptic ulcer, with a mortality rate of 9.08/100,000 person-years. Meanwhile, the mortality rate in the general population was 5.09/100,000 person-years, giving a standardized mortality ratio (SMR) of 1.78 (95% confidence interval, 1.73–1.84). Patients who are female, of other race, unmarried, and with distant tumor stage have greater SMRs. A higher SMR was associated with a younger age at diagnosis. Among those aged < 40 years at diagnosis, the plurality of fatal peptic ulcers occurred in patients with leukemia and lymphoma, while in patients aged > 40 years, the majority occurred in those with prostate, breast, colorectum, and lung cancer. Patients with upper digestive system malignancies had the highest SMRs and hazard ratios (HRs), which could be ascribed to radiotherapy-induced damage to the gastroduodenum. The risk declined rapidly one year after diagnosis. However, the SMRs in the upper digestive system cancer survivors increased significantly over ten years after diagnosis. Upper digestive system cancers adjacent to the gastroduodenum were associated with higher SMRs and HRs compared with other types of cancer, possibly contributing partially to the damage caused by radiotherapy on the radiosensitive gastroduodenum.

scholarly journals Superpixel image segmentation of VISTA expression in colorectal cancer and its relationship to the tumoral microenvironment

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Dongling Wu ◽  
Sean Hacking ◽  
Taisia Vitkovski ◽  
Mansoor Nasim
Keyword(s):  
Colorectal Cancer ◽  
Image Segmentation ◽  
T Cell Activation ◽  
Cell Activation ◽  
Disease Free Survival ◽  
Tumor Stage ◽  
The United States ◽  
Mutational Status ◽  
Microsatellite Stability

AbstractColorectal cancer (CRC) is the third most common cause of cancer related death in the United States (Jasperson et al. in Gastroenterology 138:2044–2058, 10.1053/j.gastro.2010.01.054, 2010). Many studies have explored prognostic factors in CRC. Today, much focus has been placed on the tumor microenvironment, including different immune cells and the extracellular matrix (ECM). The present study aims to evaluate the role of V-domain immunoglobulin suppressor of T cell activation (VISTA). We utilized QuPath for whole slides image analysis, performing superpixel image segmentation (SIS) on a 226 patient-cohort. High VISTA expression correlated with better disease-free survival (DFS), high tumor infiltrative lymphocyte, microsatellite instability, BRAF mutational status as well as lower tumor stage. High VISTA expression was also associated with mature stromal differentiation (SD). When cohorts were separated based on SD and MMR, only patients with immature SD and microsatellite stability were found to correlate VISTA expression with DFS. Considering raised VISTA expression is associated with improved survival, TILs, mature SD, and MMR in CRC; careful, well-designed clinical trials should be pursued which incorporate the underlying tumoral microenvironment.

Prognostic Factors of Sinonasal Squamous Cell Carcinomas Arising De Novo and From Inverted Papilloma

2020 ◽  
Vol 35 (1) ◽  
pp. 114-121
Author(s):  
Yunxia Li ◽  
Chengshuo Wang ◽  
Ru Wang ◽  
Jiamin Zhang ◽  
Honggang Liu ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Squamous Cell ◽  
De Novo ◽  
Surgical Margin ◽  
Disease Free Survival ◽  
Tumor Stage ◽  
Inverted Papilloma ◽  
Advanced Tumor Stage ◽  
Synchronous Tumor ◽  
Survival Difference

Background The prognostic factors and survival difference between inverted papilloma (IP)-associated sinonasal squamous cell carcinoma (SCC) and de novo SCC are unclear. Objective This study aimed to compare the clinical features and oncologic outcomes in patients with IP-associated SCC and de novo SCC; and additionally, to analyze the prognostic factors of the two types of SCCs. Methods Data from 173 SCC patients treated for IP-associated SCC (n = 89) and de novo SCC (n = 84), were reviewed retrospectively for demographic features, tumor characteristics, treatment modality, and clinical outcomes. 5-year overall survival (OS) and disease free survival (DFS) was analyzed using the Kaplan-Meier method, and Cox proportional hazards model was used to analyze factors influencing prognosis. Results A higher proportion of IP-associated SCC occurred in frontal and sphenoid sinus compared to de novo SCC. The two groups demonstrated similar 5-year OS and DFS (5-year OS: 63.3% and 55.4%, DFS: 45.4% and 50.1%, respectively). The metachronous tumor had a relatively better prognosis outcome than synchronous tumor and de novo SCC (5-year OS: 73.1%, 54.5% and 55.4%, respectively). Both groups showed similar loco-regional recurrence rates ( p > 0.05); however, de novo SCC tumors demonstrated an increased incidence of distant metastasis. Multivariate analysis indicated that age >70 years, advanced tumor stage and surgical margin were independent predictive factors for the risk of mortality (HR 2.047, 1.581 and 1.931, respectively). Conclusion IP-associated SCCs have an aggressive loco-regional tendency, whereas de novo SCCs have a higher aggressive distant metastatic propensity. Age, tumor stage and surgical positive margin are key factors for poor prognosis and should be routinely taken into consideration during treatment planning and subsequent surveillance.

Sign in / Sign up

Export Citation Format

Share Document